Paxlovid rebound: new study tracks how often COVID returns after treatment
NCT ID NCT05618600
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study followed 917 adults with COVID-19 who were prescribed Paxlovid. Researchers wanted to see how often people test positive again after finishing the 5-day treatment. The goal is to better understand the so-called 'Paxlovid rebound' and help guide future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Paxlovid
- What this could lead to
- If successful, this study could help doctors understand how often COVID-19 rebounds after Paxlovid treatment and who is most at risk.
- What could go wrong
- This is an observational study, not a treatment trial. It cannot prove why rebound happens or how to prevent it. Results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Scripps Research Institute
San Diego, California, 92126, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?